Artelo Biosciences Inc 2026年季度报告

FORM 10-Q (Mark One) For the quarterly period ended:June 30, 2026 or ☐TRANSITION REPORT PURSUANT TO SECTION13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number:001-38951 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) 33-1220924(IRS Employer Nevada(State or other jurisdiction of incorporation or organization) Identification No.) 505 Lomas Santa Fe, Suite 160,Solana Beach,CA USA(Address of principal executive offices) 92075(Zip Code) (858) 925-7049(Registrant’s telephone number, including area code) N/A(Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days.☒Yes☐No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files).☒Yes☐No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Accelerated filer☐Non-accelerated filer☒Smaller reporting company☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes☐No☒ The registrant had 4,595,068shares of common stock issued and outstanding as of August 11, 2026. TABLE OF CONTENTS PART I - FINANCIAL INFORMATION Item 1.Financial Statements3Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations4Item 3.Quantitative and Qualitative Disclosures About Market Risk17Item 4.Controls and Procedures17 PART II - OTHER INFORMATION Item 1.Legal Proceedings18Item 1A.Risk Factors18Item 2.Unregistered Sales of Equity Securities and Use of Proceeds18Item 3.Defaults Upon Senior Securities18Item 4.Mine Safety Disclosures18Item 5.Other Information18Item 6.Exhibits19 PART I - FINANCIAL INFORMATION Artelo Biosciences, Inc.Unaudited Consolidated Financial Statements PageConsolidated Balance Sheets as of June 30, 2026 (unaudited) and December 31, 2025F-1Consolidated Statements of Operations and Comprehensive Loss (unaudited)F-2Consolidated Statements of Stockholders’ Equity (Deficit) (unaudited)F-3Consolidated Statements of Cash Flows (unaudited)F-4Notes to the Consolidated Financial Statements (unaudited)F-5 ARTELO BIOSCIENCES, INC.Consolidated Balance Sheets(Unaudited)(In thousands, except share data) Cash and cash equivalents$4,198$600Prepaid expenses and other current assets17395Total Current Assets4,371695Operating lease right-of-use assets4664Intangible asset2,0392,039Other assets33TOTAL ASSETS$6,459$2,801 LIABILITIES AND STOCKHOLDERS’ EQUITYCurrent Liabilities Accounts payable and accrued liabilities$1,302$3,035Due to related parties111345Operating lease liabilities - current portion4240Accrued interest - convertible notes-11Accrued interest - convertible notes - related party-4Convertible notes-437Convertible notes - related party-172Total Current Liabilities1,4554,044 STOCKHOLDERS’ EQUITYPreferred Stock, par value $0.001, 23,148 shares authorized, 0 shares issued and outstanding as ofJune 30, 2026, and December 31, 2025--Common Stock, par value $0.001, 166,666,667 shares authorized and 4,188,400 and 673,008 sharesissued and outstanding as of June 30, 2026, and December 31, 2025, respectively41Additional paid-in capital73,63562,014Accumulated deficit(68,400)(63,015)Accumulated other comprehensive loss(242)(272)TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)4,997(1,272) The accompanying notes are an integral part of these unaudited consolidated financial statements. ARTELO BIOSCIENCES, INC.Consolidated Statements of Operations and Comprehensive Loss(Unaudited)(In thousands, except per share data) ARTELO BIOSCIENCES, INC.Consolidated Statements of Cash Flows(Unaudited)(In thousands) NON-CASH FINANCING AND INVESTING ACTIVITIES:Conversion of convertible notes to common stock ARTELO BIOSCIENCES, INC.Notes to the